Cargando…
Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts
Alemtuzumab (Lemtrada™) is a humanized monoclonal antibody approved in more than 50 countries. Within the European Union, alemtuzumab is indicated for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features; in th...
Autores principales: | Berger, Thomas, Elovaara, Irina, Fredrikson, Sten, McGuigan, Chris, Moiola, Lucia, Myhr, Kjell-Morten, Oreja-Guevara, Celia, Stoliarov, Igor, Zettl, Uwe K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225231/ https://www.ncbi.nlm.nih.gov/pubmed/27882532 http://dx.doi.org/10.1007/s40263-016-0394-8 |
Ejemplares similares
-
What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion
por: Vellucci, R., et al.
Publicado: (2016) -
Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing
por: Swainson, Jennifer, et al.
Publicado: (2022) -
Alemtuzumab-related thyroid disease in people with multiple sclerosis is
associated with age and brainstem phenotype at disease onset
por: Yap, Siew Mei, et al.
Publicado: (2020) -
Assisted Reproductive Techniques in Multiple Sclerosis: Recommendations from an Expert Panel
por: Oreja-Guevara, Celia, et al.
Publicado: (2023) -
Alemtuzumab in chronic lymphocytic leukemia
por: Fraser, G., et al.
Publicado: (2007)